Gerry McKenzie

Corporate Officer/Principal bei AERIE PHARMACEUTICALS, INC.

Health Technology

Profil

Gerry McKenzie is currently the Vice President-Commercial Operations at Aerie Pharmaceuticals, Inc. He previously worked as the Chief Information Officer at AEON Biopharma Sub, Inc.

Aktive Positionen von Gerry McKenzie

Unternehmen	Position	Beginn
AERIE PHARMACEUTICALS, INC.	Corporate Officer/Principal	-

Alle aktiven Positionen von Gerry McKenzie

Ehemalige bekannte Positionen von Gerry McKenzie

Unternehmen	Position	Ende
AEON Biopharma Sub, Inc. AEON Biopharma Sub, Inc. Pharmaceuticals: OtherHealth Technology AEON Biopharma Sub, Inc. is a biopharmaceutical company. It focuses on developing a proprietary botulinum toxin complex, ABP-450, for debilitating medical conditions, with an initial focus on the neurology and gastroenterology markets. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Newport Beach, CA.	Chief Tech/Sci/R&D Officer	-

Sehen Sie sich die Erfahrung von Gerry McKenzie im Detail an

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Gerry McKenzie im Detail an

Beziehungen

Beziehungen ersten Grades

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Private Unternehmen	2
Aerie Pharmaceuticals, Inc. Aerie Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on January 1, 2005 and is headquartered in Durham, NCForth Worth, TX.	Health Technology
AEON Biopharma Sub, Inc. AEON Biopharma Sub, Inc. Pharmaceuticals: OtherHealth Technology AEON Biopharma Sub, Inc. is a biopharmaceutical company. It focuses on developing a proprietary botulinum toxin complex, ABP-450, for debilitating medical conditions, with an initial focus on the neurology and gastroenterology markets. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Newport Beach, CA.	Health Technology